Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer
{{output}}
ESK981 is a potent tyrosine kinase and PIKfyve lipid kinase inhibitor. This phase II trial evaluated the efficacy of ESK981 as a single agent in patients with androgen receptor-positive (AR +) metastatic castration-resistant prostate cancer (mCRPC). Eligible p... ...
